Key result
Sympathetic hyperactivity in chronic kidney disease aggravates risk factors for sudden cardiac death, suggesting percutaneous renal sympathetic denervation as a potential therapeutic target.
Why the study?
Does percutaneous renal sympathetic denervation prevent sudden cardiac death in patients with chronic kidney disease?
Does percutaneous renal sympathetic denervation prevent sudden cardiac death in patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
The review proposes that targeting sympathetic hyperactivity with percutaneous renal sympathetic denervation may reduce the high risk of sudden cardiac death in patients with chronic kidney disease.
Several studies have shown a strong independent association between chronic kidney disease (CKD) and cardiovascular events, including death, heart failure, and myocardial infarction. Recent clinical trials extend this range of adverse cardiovascular events, also including ventricular arrhythmias and sudden cardiac death. Furthermore, other studies suggest structural remodeling of the heart and electrophysiological alterations in this population. These processes may explain the increased risk of arrhythmia in kidney disease and help to identify patients who are at increased risk of sudden cardiac death. Sympathetic hyperactivity is well known to increase cardiovascular risk in CKD patients and is a hallmark of essential hypertensive state that occurs early in the clinical course of the disease. In CKD, the sympathetic hyperactivity seems to be expressed at the earliest clinical stage of the disease, showing a direct relationship with the severity of the condition of renal failure, being more pronounced in the terminal stage of CKD. The sympathetic efferent and afferent neural activity in kidney failure is a key mediator for the maintenance and progression of the disease. The aim of this review was to show that the feedback loop of this cycle, due to adrenergic hyperactivity, also aggravates many of the risk factors responsible for causing sudden cardiac death and may be a potential target modifiable by percutaneous renal sympathetic denervation. If it is feasible and effective in end-stage renal disease, little is known.
No takes yet. Share an insight, caveat, or question.
Kiuchi et al. (2015) conducted a review in Chronic kidney disease. Percutaneous renal sympathetic denervation was evaluated. Sympathetic hyperactivity in chronic kidney disease aggravates risk factors for sudden cardiac death, suggesting percutaneous renal sympathetic denervation as a potential therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: